Top Markets
#1 Islamic Coin Islamic Coin +151.50%
#2 DOVU DOVU +48.64%
#3 Akedo Akedo +46.30%
#4 Black Phoenix Black Phoenix +34.55%
#5 Velvet Velvet +32.25%
#6 DoubleZero DoubleZero +19.36%
#7 Cross Cross +16.34%
#8 Cap Cap +15.21%
#9 Tutorial Tutorial +13.37%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.43%
Coin of the day
Islamic Coin Islamic Coin
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Pozycja w akcjach #33957
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Cena akcji
$17.15
Ostatnia synchronizacja: 2026-08-03
Kapitalizacja rynkowa
$6.51M
Zmiana (1 dzień)
9.80%
Zmiana (1 rok)
289.77%
Kraj
US
Handel Galera Therapeutics, Inc. (GRTX)

Kategoria

Healthcare
Wskaźnik P/B dla Galera Therapeutics, Inc. (GRTX)
Wskaźnik P/B na dzień August 2026 TTM: 1.53
Według najnowszych raportów finansowych i ceny akcji Galera Therapeutics, Inc., obecny wskaźnik P/B (TTM) wynosi 1.53. Na koniec 2023 wynosił -0.05.
Historia wskaźnika P/B dla Galera Therapeutics, Inc. od 2017 do 2026
Wskaźnik P/B na koniec każdego roku
Rok Wskaźnik P/B Zmień
2026 (TTM) 1.53 -7,767.00%
2024 -0.02 -64.78%
2023 -0.05 -86.64%
2022 -0.37 -81.88%
2021 -2.04 -104.91%
2020 41.59 786.53%
2019 4.69 -311.62%
2018 -2.22 -99.08%
2017 -240.04 0.00%
Wskaźnik P/B dla podobnych firm lub konkurentów
Firma Wskaźnik P/B Różnica wskaźnika P/B Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 308.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 314.00%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 136.99%
BE